Table 1.
Baseline characteristics of patients with and without detectable circulating tumor DNA using next generation sequencing
| All (n = 58) | ctDNA detected (n = 26) | No ctDNA detected (n = 32) | p | |
|---|---|---|---|---|
| Age | 67 (58–73) | 68 (59–74) | 65 (53–72) | 0.719 |
| Male sex | 31 (53.4) | 17 (65.4) | 14 (43.8) | 0.100 |
| ECOG performance status | ||||
| 0–1 | 39 (69.6) | 19 (76.0) | 20 (64.5) | 0.353 |
| 2–3 | 17 (30.4) | 6 (24.0) | 11 (35.5) | |
| Unknown | 2 | 1 | 1 | |
| CA19.9 (kU/L) | 797 (138–6,063) | 3,941 (102–78,342) | 449 (143–3,261) | 0.338 |
| Maximum diameter primary tumor (mm) | 36 (28–54) | 36 (27–58) | 36 (29–50) | 0.727 |
| Vascular involvement primary tumor1 | ||||
| No | 41 (71.9) | 7 (26.9) | 9 (29.0) | 0.860 |
| Yes | 16 (28.1) | 19 (73.1) | 22 (71.0) | |
| Unknown | 1 | 0 | 1 | |
| Metastases on baseline imaging1 | ||||
| No or distant lymph nodes only | 10 (17.5) | 0 | 10 (32.3) | <0.001 |
| Liver metastases2 | 37 (64.9) | 24 (92.3) | 13 (41.9) | |
| Metastases other than liver | 10 (17.5) | 2 (7.7) | 8 (25.8) | |
| Unknown | 1 | 0 | 1 | |
| Total tumor volume3 | 47.9 (22.7–88.9) | 70.0 (41.9–264.0) | 35.4 (18.7–65.6) | 0.004 |
| Tumor volume primary tumor3 | 25.1 (13.7–50.1) | 27.0 (18.4–69.0) | 21.5 (10.8–38.2) | 0.149 |
| Tumor volume metastases3 | 12.6 (1.7–48.9) | 36.2 (12.0–153.4) | 4.6 (0–22.2) | 0.001 |
| First line chemotherapy | ||||
| No chemotherapy | 14 (26.4) | 8 (36.4) | 6 (19.4) | 0.642 |
| FOLFIRINOX4 | 23 (39.6) | 8 (36.4) | 15 (46.9) | |
| Gemcitabin‐nabpaclitaxel4 | 16 (27.6) | 6 (27.3) | 10 (31.3) | |
| Unknown | 5 | 4 | 1 |
Continuous variables were presented as median with Interquartile ranges (IQR); Categorical variables were presented as counts with percentages.
1
On baseline imaging, baseline imaging data were missing for one patient.
2
With or without metastases to other organs.
3
Available for 47 cases.
4
At least one completed cycle of chemotherapy.